Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...
Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad, reducing their need for clinic visits. New guidance (PDF) from health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results